Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

Next Previous
Search
Trial Profile

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 64Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms COBRA
  • Sponsors Clarity Pharmaceuticals

    • Most Recent Events

    • 28 Jan 2025 According to a Clarity Pharmaceuticals media release, abstract from COBRA study is selected for an oral presentation at the American Urological Association (AUA) Annual Meeting 2025, on Sunday, April 27, 2025, 9:30 AM - 11:30 AM PT, under the session named: MP13: Prostate Cancer: Staging.
    • 28 Jan 2025 According to a Clarity Pharmaceuticals media release, abstracts from this study and CLARIFY study have been accepted for Poster presentations at the Annual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2025. A poster from COBRA study will be presented on Thursday, February 13, 2025, 11:25 AM - 12:45 PM PT under the session Trials in Progress Poster Session A: Prostate Cancer.
    • 24 Jan 2025 According to a Clarity Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions in patients with biochemical recurrence (BCR) of prostate cancer following definitive therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top